A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Chronic Hepatitis C

Interventions

DRUG

VX-135

12 weeks of VX-135

DRUG

Ribavirin

12 weeks of ribavirin

Trial Locations (1)

Arensia, Republican Clinical Hospital, Chisinau